Prevalence of pharmacotherapy for attention‐deficit/hyperactivity disorder and prescription stimulant misuse: A national study of US college students
Addiction · 2025-04 · 120 (4) · 721-731
DOI: 10.1111/add.16716 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Addiction, online erschienen am 17.11.2024. Verfasst von Alynna G Summit und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Health Science, School of Public Health, Indiana University, Bloomington, IN, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Prescription Drug Misuse, Students. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse of the National Institutes of Health.
Abstract (Originalsprache)
Background and aims Increasing rates of attention‐deficit/hyperactivity disorder (ADHD) pharmacotherapy may simultaneously benefit patients and increase the availability of stimulants for misuse. We measured the association between university‐level prevalence of ADHD medication treatment and prevalence of prescription stimulant misuse (PSM) among college students. Design, setting and participants This was an observational study using cross‐sectional data from the American College Health Association–National College Health Assessment III. Data included 395 participating universities between Fall 2019 and Fall 2022. Our sample included 224 469 undergraduates aged 18–25 years (65.2% cisgender female; 58.7% White).
Measurements
Students self‐reported any life‐time clinical ADHD diagnosis, past‐year ADHD medication treatment and past‐3‐month PSM. We defined university‐level ADHD medication prevalence as the proportion of included students endorsing past‐year ADHD medication treatment. Secondary outcomes included life‐time PSM and moderate‐ to high‐risk alcohol and cannabis use. We also measured university‐level depression medication prevalence as a negative control exposure.
Findings
Among the included students, 9.6% reported a life‐time clinical ADHD diagnosis, 5.1% reported past‐year medication treatment and 2.4% reported past‐3‐month PSM. The prevalence of ADHD medication treatment varied among universities [mean = 5.3%, standard deviation (SD) = 2.8%]. In adjusted models, prevalence of PSM was 7% relatively greater for every 1% increase in university‐level medication prevalence [adjusted prevalence ratio (aPR) = 1.07; 95% confidence interval (CI) = 1.04–1.09]. Further, individuals with non‐medication‐treated ADHD were 40% more likely to report PSM than those without ADHD (aPR = 1.40; 95% CI = 1.25–1.56). There was no statistically significant difference in PSM among individuals with ADHD who did or did not receive medication (aPR = 0.90; 95% CI = 0.78–1.04). Results for secondary outcomes and the negative control partially supported the specificity of the findings.
Conclusions
Among university students in the United States, there appears to be a positive association between attending universities with a greater prevalence of attention deficit/hyperactivity disorder (ADHD) medication treatment and risk of prescription stimulant misuse (PSM). This study provides further support for the possibility that ADHD medication treatment prevalence is a risk factor for PSM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Health Science, School of Public Health, Indiana University, Bloomington, IN, USA.
- Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.
- Department of Applied Psychology in Education and Research Methodology, Indiana University, Bloomington, IN, USA.
ORCID-Profile: Alynna G Summit, Natasha Chaku, Kit K Elam, Wura Jacobs, Alyssa M Lederer, Ellen L Vaughan, Patrick D Quinn
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse of the National Institutes of Health
Zitieren
APA
Summit, A. G., Moseley, M. C., Chaku, N., Elam, K. K., Jacobs, W., Lederer, A. M., Vaughan, E. L., & Quinn, P. D. (2025). Prevalence of pharmacotherapy for attention‐deficit/hyperactivity disorder and prescription stimulant misuse: A national study of US college students. Addiction, 120(4), 721-731. https://doi.org/10.1111/add.16716
Vancouver
Summit AG, Moseley MC, Chaku N, Elam KK, Jacobs W, Lederer AM, et al. Prevalence of pharmacotherapy for attention‐deficit/hyperactivity disorder and prescription stimulant misuse: A national study of US college students. Addiction. 2025;120(4):721-731. doi:10.1111/add.16716
BibTeX
@article{Summit2025,
author = {Summit, Alynna G and Moseley, Madison C and Chaku, Natasha and Elam, Kit K and Jacobs, Wura and Lederer, Alyssa M and Vaughan, Ellen L and Quinn, Patrick D},
title = {Prevalence of pharmacotherapy for attention‐deficit/hyperactivity disorder and prescription stimulant misuse: A national study of US college students},
journal = {Addiction},
year = {2025},
volume = {120},
number = {4},
pages = {721--731},
doi = {10.1111/add.16716}
}
EUVIMED